Swog Cancer Research Network

This study tests a web-based program called Current Together after Cancer (CTAC) to help people who had surgery for stage II or III colorectal cancer stay on track with recommended follow-up care. About 1,057 participants will use the online tool to learn about surveillance, buil…

This study tests whether using specific features of a person's lung cancer (biomarkers) can help doctors choose the best maintenance treatment to keep the cancer from growing. About 900 people with extensive-stage small cell lung cancer will receive standard initial therapy, then…

This study is for people with a type of blood cancer (large B-cell lymphoma) that has come back or not gotten better after earlier treatments, and who cannot have a stem cell transplant. The trial tests whether adding either tazemetostat or zanubrutinib to a standard two-drug com…

This study tests whether adding the targeted drug panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or cannot be removed will receive either chemo alone or che…

This study tests a drug called amivantamab, given as a shot under the skin, for people with advanced non-small cell lung cancer that has extra copies of the MET gene. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 88 participants will take par…

This study tests whether adding carboplatin to the standard chemotherapy cabazitaxel helps men with advanced prostate cancer that no longer responds to hormone therapy. About 528 participants will receive either cabazitaxel alone or cabazitaxel plus carboplatin. The goal is to se…

This study compares a shorter chemotherapy-immunotherapy regimen without anthracyclines to the standard longer treatment for people with early-stage triple negative breast cancer. About 2,400 participants will receive either the experimental shorter treatment or the usual care. T…

This study is for people with kidney cancer that has spread to other parts of the body. It compares two standard treatments: immunotherapy drugs alone versus immunotherapy plus surgery to remove the affected kidney. The goal is to see if adding surgery helps people live longer. A…

This study tests whether adding the immunotherapy drug cemiplimab to the standard two-drug combination (docetaxel and ramucirumab) can help people with advanced or recurrent non-small cell lung cancer live longer. Participants have already tried platinum-based chemotherapy and im…

This study looks at whether giving two chemotherapy drugs (capecitabine and temozolomide) after surgery can stop high-risk pancreatic neuroendocrine tumors from coming back. About 141 people who had their tumor removed will either get the chemo or just be watched. The goal is to …

This study tests two different drug combinations in people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a three-drug mix (encorafenib, binimetinib, and nivolumab), the other gets two immunotherapy drugs (ipilimumab and nivolumab). The goal is to see…

This study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard therapy plus surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps patients liv…

This study tests whether adding ramucirumab to tepotinib helps control advanced non-small cell lung cancer with a specific MET gene change. About 56 people with stage IV or recurrent cancer will receive either tepotinib alone or with ramucirumab. The goal is to see if the combina…

This study tests whether giving two additional drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy helps control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be rand…

This study tests whether giving the chemotherapy drug carboplatin before surgery can shrink tumors in men with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. About 44 participants will receive carboplatin before their prostate removal surgery. The goa…

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This study tests whether adding a stem cell transplant to standard chemotherapy works better than chemotherapy alone for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. About 338 participants will receive either chemo plus a stem …

This study compares two treatment options for people with small bowel cancer that has spread or stopped responding to standard therapy. One group gets ramucirumab plus paclitaxel, the other gets FOLFIRI chemotherapy. The goal is to see which combination better slows cancer growth…

This study tests three ways to prevent nerve damage (numbness, tingling, pain) caused by taxane chemotherapy in people with solid tumors. About 777 participants will wear special wraps that cool and/or compress their arms and legs during treatment. The goal is to see which method…

This study tests whether giving the drug lanreotide before pancreatic surgery can prevent a common complication called a pancreatic fistula—a leak of digestive fluids that can cause infection. About 274 people with pancreatic cancer or precancerous lesions will be randomly assign…

This study looks at why some people get mild or serious side effects from immunotherapy drugs used to treat cancer. Researchers will track over 2,000 patients to see how age, gender, and other health conditions affect side effects. The goal is to help doctors choose safer treatme…

This large study screens up to 10,000 people with previously treated non-small cell lung cancer to find specific genetic markers in their tumors. Based on those markers, participants may be assigned to a sub-study testing a new targeted therapy or immunotherapy. The goal is to ma…

This study watches people with HER2+ breast cancer that has spread, who are getting trastuzumab-based treatment. The main goal is to see how often heart problems happen, especially in those also taking beta blockers or other heart medications. A smaller part of the study tests if…

This study looks at whether using blood tests to decide when to do scans is as good as the usual way of monitoring breast cancer that has spread. About 739 patients will be randomly assigned to either blood test monitoring or standard care. The goal is to see if survival is simil…